Overview

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this multi-center clinical trial is to verify more effective on local control of malignant pleural effusions in NSCLC patients by thoracic cavity perfusion of recombinant human adenovirus type 5 injection and recombinant human Endostatin injection (Endostar) compared with cisplatin perfusion, with acceptable side effects.

Phase:

Phase 3

Details

Lead Sponsor:

Xinqiao Hospital of Chongqing

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Endostar protein
Endostatins
Gemcitabine
Paclitaxel
Pemetrexed
Vinorelbine